Browsing Over 32 Presentations

Sort By
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next? Educational session

The evolving role of molecular profiling for therapeutic stratification in newly diagnosed ovarian cancer (ID 3)

Lecture Time
13:35 - 13:50
Speakers
  • D. Tan (Singapore, Singapore)
Session Name
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
13:35 - 14:50
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next? Educational session

The role of surgery for newly diagnosed ovarian cancer: Current status and future directions (ID 4)

Lecture Time
13:50 - 14:05
Speakers
  • S. Mahner (Munich, Germany)
Session Name
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
13:35 - 14:50
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next? Educational session

First line maintenance therapy for ovarian cancer in 2021: What are the options? (ID 5)

Lecture Time
14:05 - 14:20
Speakers
  • I. L. Ray-Coquard (Lyon, France, CEDEX)
Session Name
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
13:35 - 14:50
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next? Educational session

Horizon scanning: What’s next for systemic therapy in ovarian cancer - first line and beyond? (ID 6)

Lecture Time
14:20 - 14:35
Speakers
  • D. Lorusso (Rome, Italy)
Session Name
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
13:35 - 14:50
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next? Educational session

Live Q&A and discussion (ID 7)

Lecture Time
14:35 - 14:50
Session Name
Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
13:35 - 14:50
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Clinical case - What options for HRD patients? Criteria for treatment choice (ID 8)

Lecture Time
15:05 - 15:25
Speakers
  • E. C. Kohn (Bethesda, United States of America)
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Clinical case - What options for HR proficient patients? Criteria for treatment choice (ID 9)

Lecture Time
15:25 - 15:45
Speakers
  • N. Colombo (Milan, Italy)
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Clinical case - Combination vs sequence: Clinical implications (ID 10)

Lecture Time
15:45 - 16:05
Speakers
  • S. Lheureux (Toronto, Canada, Ontario)
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Live Q&A and discussion (ID 11)

Lecture Time
16:05 - 16:20
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
Best of abstracts session Abstract session

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (ID 12)

Lecture Time
12:45 - 12:55
Speakers
  • A. Poveda Velasco (Valencia, Spain)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next? Educational session

Surgery in recurrent ovarian cancer: Patient selection and impact on 2nd line therapeutic strategies (ID 13)

Lecture Time
14:30 - 14:50
Speakers
  • P. Harter (Essen, Germany, 45219)
Session Name
Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
14:30 - 15:45
Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next? Educational session

Do all patients with recurrent ovarian cancer need systemic therapy and which is the optimal treatment algorithm? (ID 14)

Lecture Time
14:50 - 15:10
Speakers
  • M. L. Friedlander (Randwick, Australia)
Session Name
Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next?
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
14:30 - 15:45